Affordable HIV Injection Set to Transform Prevention in 120 Countries
A new HIV prevention drug called Lenacapavir is poised to reshape global efforts against HIV/AIDS. Thanks to negotiated agreements, over 100 low- and middle-income countries will be able to access it for the price of around US$40 per person — a dramatic drop from prior pricing. The drug, which is delivered by injection twice a year, offers a more convenient and durable alternative to daily pills.
Details & significance
Developed for HIV prevention (pre-exposure prophylaxis, PrEP) in populations where adherence to daily pills has been a challenge.
The cost has been reduced from ~$28,000 to ~$40 via collaborative efforts involving the Clinton Health Access Initiative, Gates Foundation, and participating governments.
It will be rolled out by the end of 2025 and gradually expanded across 120 countries.
Impacts & challenges
Improved adherence (twice-yearly shots) Infrastructure for delivery (cold chain, clinics)
Reaches underserved populations Health system capacity in rural / fragile regions
Cost reduction helps sustainability Negotiations with pharma, patents, regulatory approvals
Potential to reduce new HIV infections Ensuring equity, avoiding stockouts or corruption
Voices / quotes
-Global health officials / WHO on the public health impact
-HIV advocacy programs, NGOs working at local levels
-Healthcare workers in low-income countries
-Patients or target populations (if possible) sharing expectations / concerns
This development is a major leap forward for HIV prevention, especially in regions where resources are constrained. For Uganda, where HIV remains among leading health challenges, the adoption of Lenacapavir could mark a turning point—if supply, distribution, and public trust are aligned. The Urban Gazette will monitor whether Uganda is among early adopters and how implementation unfolds.
